A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03893955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.
Study identification
- NCT ID
- NCT03893955
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2019 (Actual)
- Primary completion
- Mar 2027 (Estimated)
- Completion
- Mar 2027 (Estimated)
- Last update posted
- Sep 2, 2026
2019 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group, PA /ID# 218863 | Springdale | Arkansas | 72762 | — |
| St Jude Hospital dba St Joseph /ID# 211130 | Santa Rosa | California | 95403 | — |
| Yale University School of Medicine /ID# 210678 | New Haven | Connecticut | 06510 | — |
| Moffitt Cancer Center /ID# 215037 | Tampa | Florida | 33612-9416 | — |
| Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072 | Fort Wayne | Indiana | 46804 | — |
| Washington University-School of Medicine /ID# 221399 | St Louis | Missouri | 63110 | — |
| Duplicate_Duke Cancer Center /ID# 217641 | Durham | North Carolina | 27710-3000 | — |
| Carolina BioOncology Institute /ID# 210664 | Huntersville | North Carolina | 28078 | — |
| UPMC Hillman Cancer Ctr /ID# 222747 | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology-Nashville Centennial /ID# 221400 | Nashville | Tennessee | 37203-1632 | — |
| Mary Crowley Cancer Research /ID# 210716 | Dallas | Texas | 75230 | — |
| NEXT Oncology /ID# 210717 | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists - Fairfax /ID# 210671 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03893955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03893955 live on ClinicalTrials.gov.